Author: Ken Dropiewski

Medtronic Shows Off Early Intrepid TMVR Data

DUBLIN and DENVER – November 1, 2017 – Medtronic (NYSE:MDT) today presented positive data for its self-expanding Intrepid(TM) transcatheter mitral valve replacement (TMVR) system in patients with severe, symptomatic mitral valve regurgitation. Presented as a First Report Investigation at the Transcatheter Cardiovascular Therapeutics (TCT) Annual Meeting and simultaneously published in the Journal of the American […]

Elixir Medical Corporation Unveils Transformational DynamX™ Stent Featuring Adaptive Segments that Uncage the Stented Artery

MILPITAS, Calif.–(BUSINESS WIRE)– Elixir Medical, a leader in the development of breakthrough adaptive remodeling technologies designed to mimic the normal arterial function after cardiovascular and peripheral vascular disease intervention, unveiled for the first time its novel stent technology, DynamXTM, a bioadaptive drug eluting stent (BA-DES) platform at the Transcatheter Cardiovascular Therapeutics […]

Lombard Medical Announces Shares to Trade on OTCQX

OXFORDSHIRE, U.K.–(BUSINESS WIRE)– Lombard Medical, Inc. (Nasdaq: EVAR), a medical device company focused on endovascular aneurysm repair of abdominal aortic aneurysms (AAA), today announced that it has notified Nasdaq of its intention to voluntarily delist the Company’s shares from the Nasdaq Capital Market (“Nasdaq”) and transfer its listing to the OTCQX. Lombard […]

TCT 2017: BIOTRONIK Symposium Highlights Differing Roles of Drug-Eluting Stents and Magnesium Scaffolds in Clinical Practice

Denver, United States / Buelach, Switzerland, 31.10.2017 (PresseBox) – Data presented at the BIOTRONIK-sponsored symposium on the Orsiro1 drug-eluting stent (DES) demonstrate why Orsiro is gaining prominence in the crowded DES market. In addition, clinical and preclinical data presented about Magmaris2 reinforce the case that the magnesium-based resorbable technology does not share the same risk of […]

OrbusNeich’s COMBO Dual Therapy Stent Demonstrates Non-Inferiority vs the Market Leading XIENCE™ Everolimus Eluting Stent

DENVER, October 30, 2017 /PRNewswire/ — New results from the HARMONEE Japan/US Registration Trial, reported by OrbusNeich today in the First Report Investigations session at the 29th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, demonstrate that the COMBO(TM) Dual Therapy Stent (DTS) compares favorably to the market leading option for treating patients […]

Abbott Shows off Landmark XIENCE Stent Data

DENVER, Oct. 30, 2017 /PRNewswire/ — Abbott (NYSE: ABT) today announced that patients who underwent minimally-invasive implantation with a XIENCE coronary stent for left-main coronary artery disease had the same long-lasting health outcomes at three years but felt better more quickly than patients who underwent open-heart surgery. The data were presented during […]

Transradial Interventions can Cause Permanent Vascular Damage, Study Shows

Studies over the past two decades have shown that transradial access for PTCA interventions to have an advantage over transfemoral. Specifically, that access-site and bleeding complications are nearly eliminated. This was an important advantage because although there have been advances in interventional techniques, antithrombotic therapy, and closure devices, bleeding complications […]

Analytics 4 Life to Present New Clinical Data on Novel Cardiac Imaging Technology Using Machine-Learned Algorithms at the Transcatheter Cardiovascular Therapeutics (TCT) 2017 Scientific Symposium

RESEARCH TRIANGLE PARK, N.C. and TORONTO, Oct. 30, 2017 /PRNewswire/ — Analytics 4 Life, a digital health company applying the power of artificial intelligence to develop solutions that improve existing care pathways, today announced it will be presenting new clinical data on the Company’s ongoing Coronary Artery Disease Learning and Algorithm Development (CADLAD) study at […]

Mercator MedSystems Announces Completion of Enrollment in the LIMBO-ATX Trial

EMERYVILLE, Calif., Oct. 30, 2017 /PRNewswire/ — Mercator MedSystems, Inc., a medical technology company specializing in localized delivery of drug therapies for deep in the body, announced completion of enrollment today in the company’s LIMBO-ATX (Lower-Limb Adventitial Infusion of Dexamethasone via Bullfrog to Reduce Occurrence of Restenosis after Atherectomy-Based Revascularization) clinical […]